GlaxoSmithKline - Re: GSK Stream Log - Beaufort note out this morning:...

Beaufort note out this morning: "GSK's plan to file the three-drug therapy in the US earlier than schedule is an important step taken by it. The closed triple therapy is a combination of three molecules: fluticasone furoate (FF), an inhaled corticosteroid (ICS), umeclidinium (UMEC), an anti-cholinergic, and vilanterol (VI). The therapy provides GSK an opportunity to recapture its leading position in the COPD market, which has been dented by pricing pressure and competition from other products. Meanwhile, GSK is making good progress on other therapy areas such as HIV vaccines, oncology, cardiovascular and immune inflammation. We believe GSK is moving in the right direction, supported by some world-class assets and technology, to deliver longterm growth and generate stable returns for shareholders." taken off of researchtree